The Optimal First‐Line Therapy for Extensive‐Stage Small‐Cell Lung Cancer Based on Liver Metastasis Status: A Network Meta‐Analysis and Systematic Review

Documenti analoghi

• Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer
  di: Jiayin Liu, et al.
  Pubblicazione: (2026)
• Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis
  di: Zhuoran Sun, et al.
  Pubblicazione: (2026)
• Real‐World Data of Second‐Line Amrubicin Monotherapy in Patients With Extensive‐Stage Small Cell Lung Cancer Who Received First‐Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study
  di: Kei Sonehara, et al.
  Pubblicazione: (2026)
• Association Between Antibiotic and Outcomes of Chemoimmunotherapy for Extensive‐Stage Small Cell Lung Cancer: A Multicenter Retrospective Study of 132 Patients
  di: Fang Deng, et al.
  Pubblicazione: (2024)
• Treatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States
  di: Do H. Lee, et al.
  Pubblicazione: (2026)